2024-06-01 2025-05-31 false Capium Accounts Production 1.1 12610227 2024-06-01 2025-05-31 12610227 bus:AbridgedAccounts 2024-06-01 2025-05-31 12610227 bus:FRS102 2024-06-01 2025-05-31 12610227 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 12610227 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 12610227 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 12610227 2024-06-01 2025-05-31 12610227 2025-05-31 12610227 bus:RegisteredOffice 2024-06-01 2025-05-31 12610227 core:WithinOneYear 2025-05-31 12610227 core:AfterOneYear 2025-05-31 12610227 1 2024-06-01 2025-05-31 12610227 bus:Director1 2024-06-01 2025-05-31 12610227 bus:Director1 2025-05-31 12610227 bus:Director1 2023-06-01 2024-05-31 12610227 2023-06-01 12610227 bus:LeadAgentIfApplicable 2024-06-01 2025-05-31 12610227 2023-06-01 2024-05-31 12610227 2024-05-31 12610227 core:WithinOneYear 2024-05-31 12610227 core:AfterOneYear 2024-05-31 12610227 bus:EntityAccountantsOrAuditors 2023-06-01 2024-05-31 12610227 core:ComputerEquipment 2024-06-01 2025-05-31 12610227 core:ComputerEquipment 2025-05-31 12610227 core:ComputerEquipment 2024-05-31 12610227 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-05-31 12610227 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-05-31 12610227 core:CostValuation core:Non-currentFinancialInstruments 2025-05-31 12610227 core:CostValuation core:Non-currentFinancialInstruments 2024-05-31 12610227 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-05-31 12610227 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-05-31 12610227 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-05-31 12610227 core:Non-currentFinancialInstruments 2025-05-31 12610227 core:Non-currentFinancialInstruments 2024-05-31 12610227 core:ShareCapital 2025-05-31 12610227 core:ShareCapital 2024-05-31 12610227 core:RetainedEarningsAccumulatedLosses 2025-05-31 12610227 core:RetainedEarningsAccumulatedLosses 2024-05-31 12610227 dpl:Item1 2024-06-01 12610227 dpl:Item1 2025-05-31 12610227 dpl:Item1 2023-06-01 12610227 dpl:Item1 2024-05-31 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 12610227
England and Wales
HARRYPHARMA LIMITED
Abridged Accounts
Period of accounts Start date: 01 June 2024 End date: 31 May 2025

Harrypharma Limited Contents Page For the year ended 31 May 2025
Accountants' report | 1
Statement of financial position | 2
Notes to the financial statements | 3

Harrypharma Limited Accountants' Report For the year ended 31 May 2025
Report to the directors on the preparation of the unaudited statutory accounts of Harrypharma Limited for the year ended 31 May 2025. In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Harrypharma Limited for the year ended 31 May 2025 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given us. As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at http://rulebook.accaglobal.com/. This report is made solely to the Board of Directors of Harrypharma Limited, as a body, in accordance with the terms of our engagement letter dated 10 October 2025. Our work has been undertaken solely to prepare for your approval the accounts of Harrypharma Limited and state those matters that we have agreed to state to the Board of Directors of Harrypharma Limited, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Harrypharma Limited and its Board of Directors as a body for our work or for this report. It is your duty to ensure that Harrypharma Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Harrypharma Limited. You consider that Harrypharma Limited is exempt from the statutory audit requirement for the year. We have not been instructed to carry out an audit or a review of the accounts of Harrypharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts 31 May 2025. .................................................... Martin Morrison & Co Limited Martin Morrison & Co Limited Unit 43 The Coach House 66-70 Bourne Road Bexley DA5 1LU 10 October 2025 1

Harrypharma Limited Statement of Financial Position As at 31 May 2025
| Notes | 2025 £ |  | 2024 £
--- | --- | --- | --- | ---
Fixed assets |  |  |
Tangible fixed assets | 3 | 1 |  | 1
|  | 1 |  | 1
Current assets |  |  |
Debtors |  | 5,603 |  | 3,474
Cash at bank and in hand |  | 17,923 |  | 373
|  | 23,526 |  | 3,847
Creditors: amount falling due within one year |  | (16,726) |  | (2,686)
Net current assets |  | 6,800 |  | 1,161
Total assets less current liabilities |  | 6,801 |  | 1,162
Net assets |  | 6,801 |  | 1,162
Capital and reserves |  |  |
Called up share capital |  | 2 |  | 2
Profit and loss account |  | 6,799 |  | 1,160
Shareholders' funds |  | 6,801 |  | 1,162
For the year ended 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Director's responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006 the profit and loss account has not been delivered to the Registrar of Companies. The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A). The financial statements were approved by the director on 10 October 2025 and were signed by:
------------------------------- Harry Osei Ofori Director
2

Harrypharma Limited Notes to the Abridged Financial Statements For the year ended 31 May 2025
General Information Harrypharma Limited is a private company, limited by shares, registered in England and Wales, registration number 12610227, registration address 26 The Downage, Gravesend, Gravesend, DA11 7NB. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard) Turnover Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts. Tangible fixed assets Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment | 25% Straight Line
2. | Average number of employees Average number of employees during the year was 1 (2024 : 1).
3. | Tangible fixed assets
Cost or valuation | Computer Equipment |  | Total
| £ |  | £
At 01 June 2024 | 1,105 |  | 1,105
Additions | - |  | -
Disposals | - |  | -
At 31 May 2025 | 1,105 |  | 1,105
Depreciation
At 01 June 2024 | 828 |  | 828
Charge for year | 276 |  | 276
On disposals | - |  | -
At 31 May 2025 | 1,104 |  | 1,104
Net book values
Closing balance as at 31 May 2025 | 1 |  | 1
Opening balance as at 01 June 2024 | 1 |  | 1
3